# RhyGaze

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rhygaze

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.rhygaze.com/
- Total disclosed funding: $97M
- Latest round: Series A (Jan 10, 2025)
- Investors on record: 5

## About

Founded in 2024 and based in Basel, Switzerland, RhyGaze AG focuses on gene therapy solutions designed to enhance vision. In January 2025, RhyGaze AG raised USD 86 million in series A funding led by GV, including BioGeneration Ventures, Novartis Venture Fund, ARCH Venture Partners, and F-Prime Capital. As of January 2025, the company is led by its CEO, Katherine High.

RhyGaze AG develops a gene therapy specifically for restoring vision in patients suffering from blinding retinal diseases through cone optogenetics. The company’s core product involves delivering a novel light-sensor gene to cone cells in the retina, which are crucial for high-acuity vision. The therapy aims to enhance light detection capabilities in these cells, with primary users being individuals affected by retinal conditions. RhyGaze is transitioning its gene therapy to a third-party manufacturer while preparing for human clinical trials, targeting regions with a prevalence of retinal diseases such as Europe and North America.

The company’s revenue model includes partnerships with pharmaceutical companies and healthcare providers, focusing on B2B transactions as it prepares to commercialize its gene therapy solutions.

The organization plans to use the January 2025 funding to accelerate its research and development efforts for gene therapy aimed at vision restoration.

## Funding rounds

- Series A, Jan 10, 2025, $86M — ARCH Venture Partners, Novartis Venture Fund, F-Prime Capital, BioGeneration Ventures, GV
- Seed, Jul 17, 2024, $11M — Novartis Venture Fund, BioGeneration Ventures

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Seed, Series A
- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Seed, Series A
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series A